Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.

AIDS (London, England) - 1 Dec 1996

Wainberg M A, Hsu M, Gu Z, Borkow G, Parniak M A

Abstract excerpt

OBJECTIVE: To measure the extent of HIV resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC, lamivudine) within the context of monotherapy and to assess the presence of the M184V substitution in the case of 3TC-resistant viruses. Whether the success of 3TC in clinical trials could be due, in part, to an increase in the fidelity of HIV reverse transcriptase conferred by the M184V substitution was also considered....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Child, Preschool
Share to Drug Resistance, Microbial

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Infections

Share to HIV Reverse Transcriptase

Share to Mutation

Share to Neutralization Tests

Source

Identifiers

PMID: 9030390
DOI: 10.1097/00002030-199612005-00002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.PMID 9030390Read ↗

Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.Semantic proximity Read ↗

Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.Semantic proximity Read ↗

Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.Semantic proximity Read ↗

Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.Semantic proximity Read ↗

Might the M184V substitution in HIV-1 RT confer clinical benefit?Semantic proximity Read ↗

Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.Semantic proximity Read ↗

Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine.Semantic proximity Read ↗

Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.Semantic proximity Read ↗

Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.Semantic proximity Read ↗

The influence of 3TC resistance mutation M184I on the fidelity and error specificity of human immunodeficiency virus type 1 reverse transcriptase.Semantic proximity Read ↗

Increased polymerase fidelity of lamivudine-resistant HIV-1 variants does not limit their evolutionary potential.Semantic proximity Read ↗

The impact of the M184V substitution in HIV-1 reverse transcriptase on treatment response.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.